# Biotech Rockets Amid Market Chaos!

Newsy: Bud Fox's 3 Controversial Stocks of the Day
Published: 2026-03-26T14:01:13.544Z
Source: https://newsyai.com/edition/0300d321-45e2-4035-b69a-089c7488f6dd
Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md

---

# Biotech Bullshit Bonanza: Futures Flop, Oil Balls-Up on Iran BS!

**Premarket piss-poor**—**Dow futures -0.6% ~46,400**[[1]](https://www.benzinga.com/premarket)[[2]](https://www.cnn.com/markets/premarkets), **S&P -0.7% ~6,600**[[1]](https://www.benzinga.com/premarket), **Nasdaq -0.8% ~24,200** as WTI crude **$92.93** prick-pokes higher amid Iran talk-denials and supply jitters—energy dicks stiffen, semis sag, biotechs blast off like viagra-fueled rockets.[[3]](https://oilprice.com/oil-price-charts)[[4]](https://oilprice.com/Latest-Energy-News/World-News/Oil-Prices-Spike-as-Iran-Denies-US-Talks-and-Traders-Refocus-on-Supply-Risk.html) LNAI lunatic lunge, KOD eye-orgy, WVE wipeout—bulls hump hype, bears bitch bankruptcy. First-principles fuckery ahead.[[5]](https://stockanalysis.com/markets/premarket/)

---

## 1) Lunai Bioworks (LNAI): “AI Antidote Ass-Fuck” vs “Delisting Dick-Slap”

**Why it’s loud**  
**LNAI** exploding **+127% pre to ~$0.91** topping gainer porn—traders refocus on AI-driven IP patents, chem defense consortium targeting $400M-$1.2B US countermeasure cash cow, Nasdaq hearing hype.[[1]](https://www.benzinga.com/premarket)[[5]](https://stockanalysis.com/markets/premarket/)[[6]](https://www.quiverquant.com/news/Lunai+Bioworks+(LNAI)+jumps+189%+as+traders+refocus+on+recent+IP+update+and+looming+Nasdaq+listing+decision)

**Bull case (AI biotech boner blast)**  
PRISM-like AI drug discovery pipeline for cancer/chemical threats, first licensing deals squirting revenue, Nasdaq lifeline = moonshot to $2+ if hearing humps home.[[7]](https://www.morningstar.com/news/pr-newswire/20260319la14527/lunai-bioworks-nasdaq-lnai-launches-national-chemical-defense-consortium-targeting-400m-12b-us-countermeasure-programs-3-year-ai-antidote-development-model)[[8]](https://www.investing.com/news/stock-market-news/lunai-bioworks-stock-soars-after-securing-first-licensing-deal-for-cancer-therapy-93CH-4377465)

**Bear case (penny pump pop & delist dump)**  
Nasdaq delisting sword dangling, razor-thin liquidity = volatility vomit, dilution dick-drain from offerings, microcap meme meat for rug-pull.[[9]](https://www.ainvest.com/news/lnai-plummets-18-pre-market-delisting-fears-thin-liquidity-2603)

**My take, first principles (AI moat vs scam stink)**  
Boil the biotech: Real AI IP for antidotes = defensible if consortium contracts cum, but delist = death spiral. Oil-irrelevant flyer. **Scoop $0.80-0.85**, **$1.20/$1.50 calls** patent prick—**puts $0.70** rug-ruin. Risk: Hearing haircut.[[1]](https://www.benzinga.com/premarket)

---

## 2) Kodiak Sciences (KOD): “Eyeball Erection Eternal” vs “Trial Turd Fail”

**Why it’s loud**  
**KOD** surging **+55% pre to ~$35** eye-biotech bonanza—momentum from Baker Bros. stake boost, Phase 3 progress whispers amid offering overhang lift-off.[[1]](https://www.benzinga.com/premarket)[[5]](https://stockanalysis.com/markets/premarket/)[[10]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kod/kodiak-sciences/news/why-kodiak-sciences-kod-is-up-235-after-baker-bros-boosts-st)

**Bull case (pipeline prick-power)**  
ABRACON/suprachoroidal tech for wet AMD/DME = $10B market slam, Baker Bros. $53M cum-shot signals insider jizz, Phase 3 data dump could rocket $50+.[[11]](https://finance.yahoo.com/quote/KOD)

**Bear case (history of flop-farts)**  
76% plunge on past trial trash, serial offerings = dilution dong-swing, cash burn cockblock without approvals.[[12]](https://www.marketwatch.com/investing/stock/kod?gaa_at=eafs&gaa_n=AWEtsqehBiEc6BBK4-UqFoy9fVUvMWSfycotx2LaLLDs0AGTEWRoOa-TWKFi&gaa_sig=DNsvAKJ8LMtsFOEbEQQU1Omv2gCcX6k3a7fqRcEoLBOm0mBD_6oH-pwO47bI4U_lGguTpJek7dJgTVW9Nm2G2A%3D%3D&gaa_ts=69c53fdd)

**My take, first principles (delivery tech vs data diarrhea)**  
Core the compound: Unique depot delivery = sticky if efficacy erects, but Phase 3 flops = bankruptcy balls-off. **Buy dip $32-33**, **$40/$45 calls** vision victory—**puts $30** trial turd. Risk: Data delay dick-tease.[[5]](https://stockanalysis.com/markets/premarket/)

---

## 3) Wave Life Sciences (WVE): “RNA Rimjob Rebound” vs “Losses Limp Forever”

**Why it’s loud**  
**WVE** cratering **-56% pre to ~$5.38** RNA biotech bloodbath—wider losses echo, pipeline push but revenue rim-rag, high vol volatility.[[1]](https://www.benzinga.com/premarket)[[5]](https://stockanalysis.com/markets/premarket/)

**Bull case (PRISM platform prick)**  
RNA editing for obesity/AATD/DMD/Huntington’s = multi-billion TAM, accel approval potential, Mizuho $27 PT hump.[[13]](https://www.stocktitan.net/overview/WVE)[[14]](https://www.cnbc.com/quotes/WVE)

**Bear case (burn-baby-burn bankruptcy)**  
Q4 rev dip to $17M, FY losses balloon $204M, no commercial cum yet = dilution deluge, trial trash history.[[15]](https://www.sahmcapital.com/news/content/wave-life-sciences-wve-is-down-58-after-wider-losses-and-wve-006-accelerated-approval-push-whats-changed-2026-03-08)

**My take, first principles (editing edge vs execution flop)**  
Strip the strand: Oligo precision = moat if data delivers, but cash cliff = cap-raise carcass. **Grab $5-5.20**, **$7/$9 calls** platform pop—**puts $4.50** loss limp. Risk: Trial tease turns toxic.[[5]](https://stockanalysis.com/markets/premarket/)

---

## Tape-Side Tactics (biotech blast or bust?)

- **LNAI**: **$0.80-0.85** AI antidote ass; **$1.20C/$1.50C** spreads, **P$0.70** delist dump.[[1]](https://www.benzinga.com/premarket)  
- **KOD**: **$32-33** eye erection; **$40C/$45C**, **P$30** trial trash.[[5]](https://stockanalysis.com/markets/premarket/)  
- **WVE**: **$5-5.20** RNA rebound; **$7C/$9C**, **P$4.50** burn bitch.[[1]](https://www.benzinga.com/premarket)  

Iran ignite or ice? Biotech balls or bail. DYOR, trade balls-deep.
